9-35077266-TGGCGGTA-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_004629.2(FANCG):c.637_643delTACCGCC(p.Tyr213fs) variant causes a frameshift change. The variant allele was found at a frequency of 0.00000929 in 1,614,220 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.000013 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0000089 ( 0 hom. )
Consequence
FANCG
NM_004629.2 frameshift
NM_004629.2 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 4.92
Genes affected
FANCG (HGNC:3588): (FA complementation group G) The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group G. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 9-35077266-TGGCGGTA-T is Pathogenic according to our data. Variant chr9-35077266-TGGCGGTA-T is described in ClinVar as [Pathogenic]. Clinvar id is 6719.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr9-35077266-TGGCGGTA-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FANCG | NM_004629.2 | c.637_643delTACCGCC | p.Tyr213fs | frameshift_variant | 5/14 | ENST00000378643.8 | NP_004620.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FANCG | ENST00000378643.8 | c.637_643delTACCGCC | p.Tyr213fs | frameshift_variant | 5/14 | 1 | NM_004629.2 | ENSP00000367910.4 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152222Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
1
AN:
152222
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000795 AC: 2AN: 251450Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135898
GnomAD3 exomes
AF:
AC:
2
AN:
251450
Hom.:
AF XY:
AC XY:
1
AN XY:
135898
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000889 AC: 13AN: 1461880Hom.: 0 AF XY: 0.00000963 AC XY: 7AN XY: 727238
GnomAD4 exome
AF:
AC:
13
AN:
1461880
Hom.:
AF XY:
AC XY:
7
AN XY:
727238
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152340Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74494
GnomAD4 genome
AF:
AC:
2
AN:
152340
Hom.:
Cov.:
32
AF XY:
AC XY:
1
AN XY:
74494
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Fanconi anemia complementation group G Pathogenic:6
Pathogenic, criteria provided, single submitter | clinical testing | KCCC/NGS Laboratory, Kuwait Cancer Control Center | Apr 03, 2024 | This sequence change creates a premature translational stop signal (p.Tyr213Lysfs*6) in the FANCG gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FANCG are known to be pathogenic (PMID: 12552564). This variant is present in population databases (rs587776640, gnomAD 0.007%). This premature translational stop signal has been observed in individuals with Fanconi anemia (FA) (PMID: 15657175, 24136620, 26968956). It is commonly reported in individuals of South African ancestry (PMID: 15657175, 24136620, 26968956). ClinVar contains an entry for this variant (Variation ID: 6719). For these reasons, this variant has been classified as Pathogenic.This sequence change creates a premature translational stop signal (p.Tyr213Lysfs*6) in the FANCG gene. It is expected to result in an absent or disrupted protein product. Loss-offunction variants in FANCG are known to be pathogenic (PMID: 12552564). This variant is present in population databases (rs587776640, gnomAD 0.007%). This premature translational stop signal has been observed in individuals with Fanconi anemia (FA) (PMID: 15657175, 24136620, 26968956). It is commonly reported in individuals of South African ancestry (PMID: 15657175, 24136620, 26968956). ClinVar contains an entry for this variant (Variation ID: 6719). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Feb 05, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Sep 22, 2024 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | May 01, 2005 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Dec 10, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Dec 22, 2023 | - - |
Fanconi anemia Pathogenic:3
Pathogenic, criteria provided, single submitter | research | Division of Human Genetics, National Health Laboratory Service/University of the Witwatersrand | Jul 01, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Jun 30, 2022 | The p.Tyr213LysfsX6 or c.637_643delTACCGCC variant in FANCG has been reported in the homozygous state in more than 50 individuals with Fanconi anemia (FA) (Morgan N. 2005 PMID: 15657175, Feben C. 2014 PMID: 24136620, Ghazwani Y. 2016 PMID: 26968956). This variand was identified in 0.006% (1/16256) of African chromosomes by gnomAD (http://gnomad.broadinstitute.org); however, this frequency is low enough to be consistent with a recessive carrier frequency. This variant is reported in ClinVar (variation ID: 6719). This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 213 and leads to a premature termination codon 6 amino acids downstream. Loss of function of the FANCG gene is an established disease mechanism in autosomal recessive FA. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Fanconi anemia. ACMG/AMP criteria applied: PVS1, PS4, PM2_Supporting. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 27, 2023 | This sequence change creates a premature translational stop signal (p.Tyr213Lysfs*6) in the FANCG gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FANCG are known to be pathogenic (PMID: 12552564). This variant is present in population databases (rs587776640, gnomAD 0.007%). This premature translational stop signal has been observed in individuals with Fanconi anemia (FA) (PMID: 15657175, 24136620, 26968956). It is commonly reported in individuals of South African ancestry (PMID: 15657175, 24136620, 26968956). ClinVar contains an entry for this variant (Variation ID: 6719). For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 24, 2022 | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Published functional studies demonstrate no detectable FANCG protein in lymphoblastoid cell lines from individuals homozygous for this variant (Morgan et al., 2005); Common pathogenic variant in individual of black South African background, with more than 80% of affected individuals carrying this variant (Morgan et al., 2005; Feben et al., 2015); This variant is associated with the following publications: (PMID: 24300640, 25477267, 24136620, 15657175, 26968956, 27959697, 11126723, 29843852, 26596371, 26962299, 29154021, 28185119, 32529760, 27535533) - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at